Trump's Approach To The Opioid Epidemic: Neglect Treatment, Ignore The Experts

July 6, 2017

WASHINGTON – Since taking office, President Donald Trump has systematically removed or limited the power of federal officials and government offices that have the expertise to confront the nation’s opioid epidemic. Trump asked Surgeon General Vivek Murthy to resign in late April. He still has an acting director running the Centers for Disease Control and […]

Read the full article →

'All Scientific Hands On Deck' To End The Opioid Crisis

July 6, 2017

By Nora Volkow (Director, NIDA) and Francis Collins (Director, NIH) In 2015, 2 million people had a prescription opioid use disorder and 591,000 suffered from a heroin use disorder; prescription drug misuse alone cost the nation $78.5 billion in health care, law enforcement, and lost productivity. But while the scope of the crisis is staggering, […]

Read the full article →

Heroin Addiction: How My Father Saved Me

July 6, 2017

I was a breech birth ― feet first, my head got stuck in the birth canal. My father brought me to Children’s Hospital in Boston. The doctors diagnosed me with Cerebral Palsy. They told him that the loss of oxygen to my brain had destroyed a portion of the frontal lobe. But my father was […]

Read the full article →

Intranasal Buprenorphine Alone and in Combination with Naloxone: Abuse Liability and Reinforcing Efficacy in Physically Dependent Opioid Abusers

March 16, 2016

(Source: Drug and Alcohol Dependence) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Read the full article →

Buprenorphine + Naloxone plus Naltrexone for the Treatment of Cocaine Dependence: The Cocaine Use Reduction with Buprenorphine (CURB) Study

March 8, 2016

ConclusionsBuprenorphine + naloxone, used in combination with naltrexone, may be associated with reductions in cocaine use among people who meet DSM‐IV criteria for cocaine dependence and past or current opioid dependence or abuse. This article is protected by copyright. All rights reserved. (Source: Addiction) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find […]

Read the full article →

Current Knowledge of Buprenorphine and Its Unique Pharmacological Profile

March 2, 2016

The objective was to achieve consensus on the conclusions to be drawn from this work. It was agreed that buprenorphine clearly behaves as a full [mu]-opioid agonist for analgesia in clinical practice, with no ceiling effect, but that there is a ceiling effect for respiratory depression, reducing the likelihood of this potentially fatal adverse event. […]

Read the full article →

Clinic-Based Treatment of Opioid-Dependent HIV-Infected Patients Versus Referral to an Opioid Treatment Program: A Randomized Trial.

March 2, 2016

Conclusion: Management of HIV-infected, opioid-dependent patients with a clinic-based BUP strategy facilitates access to opioid agonist therapy and improves outcomes of substance abuse treatment. Primary Funding Source: Health Resources and Services Administration Special Projects of National Significance program. PMID: 20513828 [PubMed – in process] (Source: Annals of Internal Medicine)

Read the full article →

Opioid-Dependent Patients Respond to Therapy

March 2, 2016

Major Finding: Office-based buprenorphine/naloxone treatment was associated with a statistically significant decrease in participants reporting illegal activity, from 19% to 2%, and in interacting with the legal system, from 16% to 1%. (Source: Family Practice News)

Read the full article →

Office-Based Treatment Effective for Opioid Dependence

March 2, 2016

Major Finding: Office-based buprenorphine/naloxone treatment was associated with a statistically significant decrease in participants reporting illegal activity, from 19% to 2%, and in interacting with the legal system, from 16% to 1%. (Source: Internal Medicine News)

Read the full article →

Office-Based Opioid Treatment Keeps Ex-Inmates Out of Jail

March 2, 2016

MINNEAPOLIS — Opioid-dependent patients with a history of incarceration do well with office-based buprenorphine/naloxone therapy and have fewer interactions over time with the legal and criminal justice systems, according to a data analysis of a previous randomized, controlled trial. (Source: Clinical Psychiatry News) MedWorm Sponsor Message: Directory of the best January Sales in the UK. […]

Read the full article →